Lumos Diagnostics Holdings Ltd (ASX: LDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Lumos Diagnostics Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $24.61 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 562.99 million
Earnings per share -0.020
Dividend per share N/A
Year To Date Return -44.52%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Lumos Diagnostics Holdings Ltd (ASX: LDX)
    Latest News

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    2 ASX healthcare shares rocketing over 16% on Big US news

    These companies are making their shareholders smile on Thursday. But why?

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    3 ASX healthcare shares rocketing 20% to 100% today

    These ASX shares are thumping the market on Tuesday and making their shareholders smile.

    Read more »

    Man pointing at a blue rising share price graph.
    Healthcare Shares

    Lumos Diagnostics share price rockets 1,036% in 2 days on FDA news

    Investors are sending the Lumos Diagnostics share price through the roof following news from the US Food and Drug Administration.

    Read more »

    A woman holds a glowing, sparking, technological representation of a planet in her hand.
    Ask a Fund Manager

    Expert reveals one IPO he's absolutely pumped about. When will it hit the ASX?

    Ask A Fund Manager: SG Hiscock's Rory Hunter tells why he's looking forward to one possible listing coming up later…

    Read more »

    Two kids in superhero capes.
    Ask a Fund Manager

    2 small-cap ASX shares to handsomely reward patient investors

    Ask A Fund Manager: SG Hiscock's Rory Hunter reveals the 2 little-known stocks that will put smiles on investor faces…

    Read more »

    A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
    Coronavirus News

    Why are ASX COVID test shares climbing today?

    COVID-19 tests are in focus again today.

    Read more »

    a group of young people dance together with their hands in the air, moving to music.
    Healthcare Shares

    The Lumos Diagnostics (ASX:LDX) share price is soaring another 8% today. Here's why

    The company's shares are continuing their positive run in February.

    Read more »

    Rapid Antigen Test taking place.
    Healthcare Shares

    Why the Lumos Diagnostics (ASX:LDX) share price is up 15% today

    The company's shares are on the move today...

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    AnteoTech (ASX:ADO) share price gains 42% in a week amid RAT race

    The demand for rapid antigen tests appear to be pushing the company's shares higher.

    Read more »

    a group of doctors and medical staff in uniform high five in celebration in a hospital setting
    Healthcare Shares

    Lumos Diagnostics (ASX:LDX) share price climbs amid RAT mania

    Lumos share price rises amid RAT test drama

    Read more »

    Share Gainers

    Lumos Diagnostics (ASX:LDX) share price up 9% on evaluation update

    Another gust of wind behind Lumos Diagnostics' shares today.

    Read more »

    doctor and nurse attend to patient bedside in medical setting
    IPOs

    Lumos Diagnostics (ASX:LDX) share price adds 9% on IPO, raising $63m

    Lumos hits the ASX, riding COVID testing momentum.

    Read more »

    LDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Lumos Diagnostics Holdings Ltd

    Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

    LDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Nov 2024 $0.03 $0.00 0.00% 4,579,942 $0.03 $0.04 $0.03
    19 Nov 2024 $0.03 $0.00 0.00% 1,449,952 $0.03 $0.03 $0.03
    18 Nov 2024 $0.03 $0.00 0.00% 988,713 $0.03 $0.03 $0.03
    15 Nov 2024 $0.03 $0.00 0.00% 2,041,078 $0.03 $0.03 $0.03
    14 Nov 2024 $0.03 $0.00 0.00% 2,506,205 $0.03 $0.03 $0.03
    13 Nov 2024 $0.03 $0.00 0.00% 1,055,446 $0.03 $0.03 $0.03
    12 Nov 2024 $0.03 $0.00 0.00% 2,741,766 $0.03 $0.03 $0.03
    11 Nov 2024 $0.03 $0.00 0.00% 1,037,143 $0.03 $0.03 $0.03
    08 Nov 2024 $0.03 $0.00 0.00% 1,066,955 $0.03 $0.03 $0.03
    07 Nov 2024 $0.03 $0.00 0.00% 2,678,636 $0.04 $0.04 $0.03
    06 Nov 2024 $0.03 $0.00 0.00% 753,930 $0.03 $0.04 $0.03
    04 Nov 2024 $0.04 $0.00 0.00% 428,447 $0.03 $0.04 $0.03
    01 Nov 2024 $0.04 $0.00 0.00% 179,368 $0.04 $0.04 $0.04
    31 Oct 2024 $0.04 $0.00 0.00% 1,549,975 $0.03 $0.04 $0.03
    30 Oct 2024 $0.03 $0.00 0.00% 2,638,912 $0.04 $0.04 $0.03
    29 Oct 2024 $0.04 $0.00 0.00% 9,120,687 $0.04 $0.04 $0.04
    28 Oct 2024 $0.04 $0.00 0.00% 753,239 $0.04 $0.04 $0.04
    25 Oct 2024 $0.04 $0.00 0.00% 2,196,922 $0.04 $0.04 $0.04
    24 Oct 2024 $0.04 $0.00 0.00% 1,133,913 $0.04 $0.04 $0.04
    23 Oct 2024 $0.04 $0.00 0.00% 1,172,276 $0.04 $0.04 $0.04
    22 Oct 2024 $0.04 $0.00 0.00% 805,103 $0.05 $0.05 $0.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Oct 2024 Bronwyn Le Grice Issued 60,970 $2,316
    Rights issue.
    09 Oct 2024 Catherine Robson Issued 734,940 $27,927
    Rights issue.
    09 Oct 2024 Samuel Lanyon Issued 137,362 $5,219
    Rights issue. As per announcement on 10-10-2024
    11 Jun 2024 Catherine Robson Buy 312,500 $10,625
    On-market trade.
    07 Jun 2024 Samuel Lanyon Buy 250,000 $7,500
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Bronwyn Joyce Le Grice Non-Executive Director Nov 2020
    Ms Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy. Formerly an Investment Director with healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was involved in over $30M of portfolio investments. In 2017, she founded ANDHealth, Australia's dedicated digital health accelerator and commercialization support organization which has led to growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles in Australia and internationally, and is a Director of ANDHealth Pty Ltd. She is Chair of the Disclosure Committee and member of Risk Committee.
    Ms Catherine Robson Non-Executive Director Dec 2020
    Ms Robson has more than 20 years of experience in management, finance and investment. Ms. Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms. Robson's other Board appointments include serving as a Non-Executive Director for Australia's customer owned bank, Newcastle Greater Mutual Group, where she chairs the Audit Committee. She is Chair of the Risk Committee.
    Ms Lawrence Mehren Non-Executive Deputy ChairmanNon-Executive Director Dec 2020
    Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its Accelerate Pheno instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice.
    Mr Samuel Ross Garland Lanyon Non-Executive ChairmanNon-Executive Director Jun 2022
    Mr Lanyon has more than 25 years of experience in strategy, sales and operations with a track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation, and Vision Systems Ltd where he was responsible for establishing Vision Biosystem's sales, marketing, and service operations throughout the EU, Middle East, Latin America, and Asia Pacific. He is member of the Disclosure Committee and Risk Committee.
    Mr Doug Ward Chief Executive OfficerManaging Director Jun 2022
    Mr Ward has more than 30 years of biotech and medical technology experience at global healthcare companies including Roche, GE, Siemens, Bayer, Chiron and Hologic. During his career, Mr. Ward has held executive positions where he developed and implemented novel business strategies and introduced products to the practice of medicine. Prior to joining Lumos, he served as Vice President, Strategy and Business Development at Hologic where he led a global team responsible for fostering innovation in women's healthcare to improve clinical results. Mr. Ward also served as the CEO of Personal Genome Diagnostics (PGDx) where he led the organization's transformation from a clinical laboratory testing service into a fully functional molecular invitro diagnostics (IVD) company. He brings experience across all company functions, including Commercial Leadership, R&D, Operations, Quality, Regulatory, Service, and Support.
    Ms Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -
    Ms Tracy Weimar Company Secretary
    -
    Barrie Lambert Chief Financial Officer
    -
    Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -
    Sacha Dopheide Chief Technology Officer
    -
    Tracy Weimar Company Secretary
    -
    Sarah Glubka Senior Director of Human Resources
    -
    Annie Bell Senior Director of Medical Affairs
    -
    Paul Kase Senior Vice President Commercial Operations
    -
    Mike Raymundo Vice President of Product Development
    -
    Jon Gary Vice President of Research and Development
    -
    Sue Hibbeln Vice President Quality and Regulatory Affairs
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 83,463,862 17.34%
    Planet Innovation Holdings Limited 68,021,060 14.13%
    J P Morgan Nominees Australia Pty Limited 23,765,171 4.94%
    GZ Family Holdings Pty Ltd 11,860,707 2.46%
    Palm Beach Nominees Pty Limited 11,500,000 2.39%
    Mr Lawrence Wing Ming Ho and Mrs Ying Ho 11,000,000 2.29%
    Spiceme Capital Pty Ltd 10,000,000 2.08%
    Mr Kenneth Graham Miller 5,398,165 1.12%
    City Comfort Pty Ltd 5,102,078 1.06%
    Mr Garry Temple 4,730,809 0.98%
    Bowvale Investments Pty Limited 4,312,095 0.90%
    Paranji Super Fund Pty Ltd 4,000,000 0.83%
    Ms Yan Chen 3,548,868 0.74%
    Mr Jordan Edward Duncan Whicker 3,000,000 0.62%
    Colonial First State Inv Ltd 2,882,383 0.60%
    Mr Farouk Ahmed 2,800,000 0.58%
    Pineleaf Pty Limited 2,782,792 0.58%
    Garry Temple Pty Ltd 2,742,644 0.57%
    BNP Paribas Nominees Pty Ltd 2,729,215 0.57%
    Citicorp Nominees Pty Limited 2,697,268 0.56%

    Profile

    since

    Note